Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Dec 1:4:2050313X16683624.
doi: 10.1177/2050313X16683624. eCollection 2016.

Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules

Ali Raufi  1 , Mohamed Alsharedi  1 , Yousef Khelfa  1 , Doreen C Griswold  1 , Yehuda Lebowicz  1
Affiliations
Case Reports

Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules

Ali Raufi et al. SAGE Open Med Case Rep. .

Abstract

Chronic lymphocytic leukemia, the most common adult leukemia worldwide, is considered an indolent but incurable non-Hodgkin lymphoma. Leukemia cutis is an uncommon manifestation of chronic lymphocytic leukemia. We present a case of an adult patient who presented with skin lesion of bilateral ears, which led to the diagnosis of chronic lymphocytic leukemia. We also reviewed the cases of auricular involvement in chronic lymphocytic leukemia patients reported in the literature. Local treatment is indicated in case of leukemia cutis; however, systemic treatment is recommended when there are systemic signs and symptoms. Better awareness of disease evolution and prompt diagnosis of this leukemia cutis of chronic lymphocytic leukemia will improve the effectiveness and outcome of its management.

Keywords: Chronic lymphocytic leukemia; ear involvement; leukemia cutis.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Leukemia cutis as bilateral helical lesion before and after chemotherapy.
Figure 2.
Figure 2.
(a) Histopathology demonstrating dense mononuclear cell infiltrate (hematoxylin and eosin; 10×), (b) immunohistochemical (IHC) stains strongly and diffusely positive for CD20, (c) IHC stain positive for CD5; 40× and (d) IHC stain positive for CD23; 40×.
See this image and copyright information in PMC

References

    1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446–5456. - PMC - PubMed
    1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376(9747): 1164–1174. - PubMed
    1. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17(7): 928–942. - PubMed
    1. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12): 1101–1110. - PubMed
    1. Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2015. CA: Cancer J Clin 2015; 65(1): 5–29. - PubMed

Publication types

LinkOut - more resources